Medicare Spending Would Increase $2.0 to $5.1 Billion With Lecanemab

THURSDAY, May 18, 2023 (HealthDay News) -- If eligible patients received lecanemab, Medicare would spend an extra $2.0 to $5.1 billion annually, according to a research letter published online May 11 in JAMA Internal Medicine to coincide with the annual meeting of the Society of General Internal Medicine, held from May 10 to 13 in Aurora, Colorado.
Julia Cave Arbanas, from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues used validated cognitive measures to estimate mild cognitive impairment (MCI) or mild dementia prevalence in a cross-sectional study of traditional Medicare and Medicare Advantage beneficiaries aged 65 years or older. Applying clinical trial age and comorbidity restrictions and calculating dosages, the annual Medicare spending on lecanemab and ancillary costs were estimated.
The researchers found that 16.2 percent of the 7,588 2018 Health and Retirement Study participants had MCI or mild dementia, representing 44 million Medicare beneficiaries. The total annualized weight-based medication costs were $25,851 per beneficiary. Ancillary costs were $7,330 and increased the total costs by 28 percent per patient. Medicare would spent $2.0 billion annually if 85,687 (lower bound) eligible patients received lecanemab and would spend $5.1 billion annually if 216,536 (upper bound) eligible patients received lecanemab. The estimated annual coinsurance could reach $6,636 per patient.
"Despite incorporating increases in cognitive screening and case positivity rates, these estimates are conservative," the authors write. "Changes in physician behavior, cognitive screening capacity and demand, new diagnoses of MCI or mild dementia, and associated spending may increase more than anticipated."
Abstract/Full Text (subscription or payment may be required)
Related Posts
Could Herpes Viruses Help Drive Type 2 Diabetes?
TUESDAY, May 17, 2022 (HealthDay News) -- Certain common viruses, including the...
RSNA: 20-Year Survival Shows Lung Cancer Screening Effective
THURSDAY, Dec. 8, 2022 (HealthDay News) -- There is a high cure rate for...
Un nuevo tipo de antibiótico podría luchar contra las ITU difíciles de tratar
VIERNES, 4 de noviembre de 2022 (HealthDay News) -- El mundo necesita de forma...
La FDA estira el suministro de vacuna contra la viruela del simio al autorizar dosis más bajas
MIÉRCOLES, 10 de agosto de 2022 (HealthDay) -- Mientras los estadounidenses en...